Skip to content
thestock.space

Aarey Drugs & Pharmaceuticals (AAREYDRUGS) had a P/E of 73.3× on 6 Nov 2026, above the industry P/E of 28.7×. Sales and net profit grew 4.5% and 1.7% a year over 3 years; its ROCE of 6.6% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. Debt is 0.40× equity. It is a small-cap company with a market cap of ₹343 Cr, ranked 86th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 11% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹105.15
Day high
₹108.57
Day low
₹105.15
Prev. close
₹109.38
Volume
47.7K

Health check

1 fair · 5 to check
  • ReturnsBehind

    +11.4% over a year, better than 2 of 7 peers.

  • Price tagPricier

    P/E 73.3 vs industry 28.7.

  • GrowthSlow

    Sales +4.5%, profit +1.7% a year over 3 years.

  • ProfitabilityWeak

    ROCE 6.6% vs peer median 17.9%.

  • Balance sheetFair

    Debt 0.40× equity, interest covered 2.2×, Piotroski 7 of 9.

  • Red flags5 to check

    Return on equity is low at 2.7%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹343 Cr, #86 of 154 in its industry by size.

High beta

Beta 1.20 vs the NIFTY 50: swings more than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹415 Cr · profit ₹4 Cr
Market cap
₹343 Cr
Small cap
P/E
73.3
Industry 28.7
Price to book
2.04
Peers 4.99
Dividend yield
0.00%
ROE
2.7%
Peers 14.7%
ROCE
6.6%
Peers 17.9%
Debt to equity
0.40
Debt ₹61 Cr
EPS (TTM)
₹1.47
Face value ₹10
OPM (TTM)
1.6%
Net margin 0.9%
Sales growth
−56.3%
Latest quarter vs a year ago
Profit growth
−25.3%
Latest quarter vs a year ago
Price to sales
0.83
EV/EBITDA 54.6

Strengths and risks

Risks to check

  • Return on equity is low at 2.7%.
  • Quarterly profit down 25.3% on a year ago.
  • Quarterly sales down 56.3% on a year ago.
  • P/E of 73.3 against an industry P/E of 28.7.
  • Interest coverage of only 1.6×.

No standout strengths in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Aarey Drugs & Pharmaceuticals

Aarey Drugs & Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients, intermediates, and specialty chemicals for various industrial applications in India. The company offers intermediates, including mono methyl urea, di methyl urea, ortho para nitro anisole, 2-bromomethyl-1,3-dioxolane, and uracil. It also provides active pharmaceutical ingredients, such as metformin HCl, mefenamic acid, and doxofylline. In addition, the company…

Headquarters
Mumbai
Sector
Healthcare
ISIN
INE198H01019
Website
aareydrugs.com

Price range

52 weeks

₹50.31₹114.80

Today

₹105.15₹108.57
Avg volume (3M)
2.2 L
1-year return
plus 11.4%
From 52-week high
minus 6.2%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.87%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.30%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.81%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.59%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.93%minus 6.6%
AAREYDRUGSAarey Drugs & Pharmaceuticals107.72minus 1.52%34373.32.046.6%2.7%1.6%4.5%1.7%0.00%plus 11.4%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.59%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
10284.296.418944.6
10181.597.918543.3
1.72.6−1.54.31.3
1.7%3.1%−1.6%2.3%3.0%
1.50.84.2−0.41.7
11.30.91.81.7
0.50.70.80.80.9
1.71.50.91.30.5
20.7%30.9%38.3%−21.7%−98.5%
1.410.61.61
0.480.360.200.550.36

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+4.5%
Profit CAGR 3Y
+1.7%
EPS CAGR 3Y
−2.3%
ROE
2.7%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
413395472471
–minus 4.3%+19.6%minus 0.3%
409391469464
3.64.537.2
0.9%1.1%0.6%1.5%
6.76.895.7
2.64.33.94.6
1.61.71.92.9
−0−000
65.36.15.4
37.3%12.3%34.1%26.7%
3.84.744
–+24.2%minus 14.1%minus 1.4%
1.491.841.411.39

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
25.428.128.528.5
92105110122
37.731.434.950
13613911796.9
291303291297
13.91315.625.6
–––8.1
0.41.42.13
1.12.93.23.4
276286270257
291303291297

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
−1.3−310.310.1
0.4−1.7−5.9−12.4
1.45.6−4.52.2
0.50.9−0.1−0.1
−1−0.7−5.2−12.4
−2.3−3.75.1−2.3

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 1.8% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you